Oragenics Inc
$ 0.50
2.14%
31 Jul - close price
- Market Cap 2,211,800 USD
- Current Price $ 0.50
- High / Low $ 0.51 / 0.49
- Stock P/E N/A
- Book Value 1.41
- EPS -1.42
- Next Earning Report 2026-08-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.06 %
- ROE -3.11 %
- 52 Week High 1.45
- 52 Week Low 0.48
About
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company is headquartered in Tampa, Florida.
Analyst Target Price
$2.00
Quarterly Earnings
| Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-08 | 2025-11-07 | 2025-08-08 | 2025-05-09 | 2025-03-14 | 2024-11-13 | 2024-08-09 | 2024-05-15 | 2024-03-29 | 2023-11-09 | 2023-08-14 | 2023-05-12 |
| Reported EPS | -0.51 | -1.96 | -3.1 | -3.65 | -0.2664 | -0.3773 | -0.509 | -0.701 | -4.1378 | -0.8543 | -1.5066 | -42.3 |
| Estimated EPS | None | 0 | 0 | None | None | None | None | None | None | None | -3 | -90.01 |
| Surprise | 0 | -1.96 | -3.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.4934 | 47.71 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | 49.78% | 53.0052% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-14 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OGEN
2026-07-29 05:43:07
This article provides a risk assessment for Oragenics Inc (OGEN), noting its current score of 2.55 and ranking 206 out of 385 in the Biotechnology & Medical Research industry. The company's beta value of 1.27 suggests high volatility relative to the S&P 500. The report details various metrics including maximum drawdown, volatility, return-to-drawdown ratio, skewness, and liquidity.
2026-07-27 02:12:00
This article details the shareholder structure of Oragenics Inc (OGEN), listing major shareholders by proportion and type. It also provides institutional shareholding data across several quarters, including changes in the number of institutions and shares held. The report further highlights recent shareholder activity, showing changes in holdings by specific entities.
2026-07-26 07:42:11
The article provides a detailed financial overview of Oragenics Inc. (OGEN), including its stock performance, key financial indicators, and historical data from income statements, balance sheets, and cash flow statements. It highlights the company's latest earnings report and projected future earnings, along with year-over-year changes in various financial metrics. The document emphasizes the importance of these financial data points for investors making smart decisions.
2026-07-26 07:42:11
This article provides the quarterly and annual cash flow statements for Oragenics Inc (OGEN), including operating, investing, and financing cash flows, with data extending back to FY2012Q1. It details changes in various cash flow components and offers FAQs explaining operating, investing, financing, and free cash flows. The financial data serves to evaluate the company's financial soundness and stability over time.
2026-07-24 13:40:31
The article provides an overview of Oragenics Inc (OGEN)'s institutional confidence, based on institutional shareholding and shareholder activity. It lists various institutions and individuals, along with their shares held and the percentage change in their holdings. The Institutional Confidence score for OGEN is 3.00, with no recent change.
2026-07-24 13:12:00
This article provides a financial health analysis of Oragenics Inc (OGEN) by TradingKey. The company currently holds a financial score of 6.79, ranking 213 out of 386 in its industry, indicating a robust financial status despite low operating efficiency. Various financial metrics related to quality of earnings, operational efficiency, growth potential, and shareholder returns are mentioned, though specific data are noted as not yet disclosed by the company.
